# Heat-Treated Lacticaseibacillus rhamnosus Strains Modulate Inflammatory and Metabolic Processes in In Vitro Systems Relevant to Canine Osteoarthritis

## TL;DR

Heat-treated Lacticaseibacillus rhamnosus strains may help reduce inflammation and support joint health in dogs, offering a new approach to managing osteoarthritis.

## Contribution

Identifies two heat-treated Lacticaseibacillus rhamnosus strains with anti-inflammatory and collagen-synthesizing properties in canine models.

## Key findings

- Heat-treated Lacticaseibacillus rhamnosus strains reduce inflammation and increase type II collagen synthesis in canine chondrocytes.
- The strains improve gut health, reduce fat accumulation, and enhance muscle function in Caenorhabditis elegans models.
- These findings suggest the strains could target multiple risk factors for canine osteoarthritis.

## Abstract

What are the main findings?
Heat-treated Lacticaseibacillus rhamnosus strains (PRIOME® JH and HT-PB01) exhibited anti-inflammatory activity and type II collagen synthesis in cultured canine chondrocytes.In Caenorhabditis elegans models, both strains mitigate intestinal permeability, reduce fat accumulation, and enhance muscle structure and functionality, suggesting their potential to reduce risk factors associated with osteoarthritis.

Heat-treated Lacticaseibacillus rhamnosus strains (PRIOME® JH and HT-PB01) exhibited anti-inflammatory activity and type II collagen synthesis in cultured canine chondrocytes.

In Caenorhabditis elegans models, both strains mitigate intestinal permeability, reduce fat accumulation, and enhance muscle structure and functionality, suggesting their potential to reduce risk factors associated with osteoarthritis.

What are the implications of the main findings?
These results identify PRIOME® JH and HT-PB01 as promising postbiotic candidates for further investigation regarding their potential benefit for canine joint health.This study provides a preclinical basis for future in vivo investigation aimed at evaluating postbiotic strategies to address multiple risk factors associated with canine osteoarthritis.

These results identify PRIOME® JH and HT-PB01 as promising postbiotic candidates for further investigation regarding their potential benefit for canine joint health.

This study provides a preclinical basis for future in vivo investigation aimed at evaluating postbiotic strategies to address multiple risk factors associated with canine osteoarthritis.

Canine osteoarthritis is a progressive degenerative joint condition characterized by inflammation, structural damage, pain, and impaired joint function. Osteoarthritis risk is influenced not only by well-established factors such as age, genetics, obesity and underlying arthropathies, but also by systemic conditions such as low-grade inflammation and sarcopenia. Current interventions are primarily focused on pain relief rather than mitigating physiological impairment, despite recent veterinary guidelines. In this study, several preclinical models were employed to identify postbiotic candidates with potential to promote canine joint health. An initial screening of nine heat-treated bacterial strains identified two Lacticaseibacillus rhamnosus strains, PRIOME® JH and HT-PB01, which demonstrated significant anti-inflammatory activity on canine chondrocytes. Further characterization revealed that these two strains significantly increased type II collagen synthesis in canine chondrocytes and modulate immune responses in canine macrophages, enhancing Interleukin-10 secretion over Interleukin-12. Additionally, both strains showed potential in mitigating risk factors such as gut inflammation and permeability, fat accumulation and sarcopenia in Caenorhabditis elegans models. In conclusion, this study identified two promising postbiotic candidates, PRIOME® JH and HT-PB01, with the potential to target key risk factors associated with osteoarthritis through multifactorial mechanisms. These findings emphasize conducting dog clinical trials to evaluate their relevance in osteoarthritis.